B. Riley Research Analysts Raise Earnings Estimates for CNTA

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – Investment analysts at B. Riley lifted their FY2024 earnings estimates for shares of Centessa Pharmaceuticals in a report issued on Tuesday, November 12th. B. Riley analyst M. Mamtani now expects that the company will post earnings per share of ($1.54) for the year, up from their prior forecast of ($1.70). B. Riley has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.68) per share. B. Riley also issued estimates for Centessa Pharmaceuticals’ Q4 2024 earnings at ($0.40) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.55) EPS, FY2026 earnings at ($1.87) EPS and FY2027 earnings at ($2.18) EPS.

Several other research analysts have also weighed in on the company. Guggenheim increased their price objective on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Oppenheimer reiterated an “outperform” rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. Jefferies Financial Group boosted their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $11.00 to $26.00 in a research report on Thursday, September 19th. Finally, BMO Capital Markets upped their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, September 16th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $25.17.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock opened at $17.50 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 13.29. The firm has a 50 day simple moving average of $15.87 and a 200-day simple moving average of $12.07. Centessa Pharmaceuticals has a 1-year low of $5.58 and a 1-year high of $18.74.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05.

Institutional Trading of Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. raised its stake in Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after acquiring an additional 826 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Centessa Pharmaceuticals by 103.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after purchasing an additional 1,509 shares during the period. Quarry LP increased its position in Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after buying an additional 3,108 shares during the period. Sandia Investment Management LP purchased a new stake in Centessa Pharmaceuticals in the second quarter valued at approximately $90,000. Finally, Fred Alger Management LLC acquired a new stake in shares of Centessa Pharmaceuticals in the second quarter valued at approximately $99,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Insider Activity

In other news, insider Gregory M. Weinhoff sold 25,000 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $15.00, for a total transaction of $375,000.00. Following the completion of the transaction, the insider now directly owns 223,369 shares of the company’s stock, valued at approximately $3,350,535. This represents a 10.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Saurabh Saha sold 2,592 shares of the firm’s stock in a transaction dated Wednesday, October 23rd. The stock was sold at an average price of $15.32, for a total value of $39,709.44. Following the sale, the chief executive officer now directly owns 630,661 shares in the company, valued at $9,661,726.52. This trade represents a 0.41 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 325,031 shares of company stock worth $5,213,043. 11.59% of the stock is currently owned by corporate insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.